INTRA CELLULAR

ITCI NASDAQ
13.91
-0.24
-1.70%
After Hours: 13.85 -0.06 -0.43% 16:25 06/18 EDT
Open
14.15
Prev Close
14.15
High
14.41
Low
13.74
Volume
611.49K
Avg Vol (3M)
356.46K
52 Week High
23.62
52 Week Low
10.21
% Turnover
1.11%
Market Cap
766.92M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers INTRA CELLULAR ITCI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
MORE >

Recently

Name
Price
%Change